Expert consensus on the pharmacy of glucokinase agonist dorzagliatin
Glucokinase agonist dorzagliatin is a new oral antidiabetic drug independently developed in China,which provides a new drug option for type 2 diabetic patients newly diagnosed or poorly controlled with metformin.In order to standardize the clini-cal application of dorzagliatin and deepen the understanding of medical workers on the patient choice,usage and dosage,drug inter actions,and adverse reactions,led by Beijing Hospital,the National Center for Gerontology,Geriatric Pharmacy Professional Committee of China Medical Education Association,and Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association organized relevant clinical medicine,pharmacy and evidence-based experts to develop the consensus after three rounds of expert opinion collection and thorough discussion by using the Delphi method based on evidence-based evidence and clinical practice.A total of 9 recommendations were formulated,which will provide reference for the rational use of dorzagliatin in clinical practice.
NETL
NSTL
万方数据
